The User's Guide to Amivantamab.

Area of Science:

• Oncology
• Pharmacology
• Immunology

Background:

• Epidermal growth factor receptor (EGFR) exon20ins mutations in non-small-cell lung cancer (NSCLC) confer resistance to traditional tyrosine kinase inhibitors.
• Amivantamab is a novel therapy targeting these resistant mutations through multiple mechanisms, including immune cell recruitment.
• Approved indications for amivantamab span frontline and later-line settings for EGFR exon20ins NSCLC, and combination therapies for EGFR-sensitizing mutations.

Purpose of the Study:

• To provide a comprehensive review of amivantamab's mechanism of action, pharmacology, and clinical trial data.
• To guide clinicians in managing the unique toxicities associated with amivantamab treatment.
• To serve as a practical reference for healthcare professionals and researchers managing NSCLC patients.

Main Methods:

• Review of published clinical trial data on amivantamab in NSCLC.
• Analysis of amivantamab's pharmacological properties and mechanisms of action.
• Synthesis of information on managing amivantamab-related side effects.

Main Results:

• Amivantamab demonstrates efficacy in NSCLC with EGFR exon20ins mutations, approved in various settings.
• The drug's unique mechanisms involve bypassing resistance mutations and engaging immune responses.
• Management strategies for amivantamab-associated toxicities, linked to EGFR and MET pathway inhibition, are crucial.

Conclusions:

• Amivantamab represents a significant advancement in treating specific NSCLC subtypes, particularly those with EGFR exon20ins mutations.
• Effective management of amivantamab's side effects is essential for maximizing therapeutic benefits and patient outcomes.
• This review provides valuable insights for clinicians and researchers involved in NSCLC targeted therapy.